AI Discovery Deals Dominate
The day's biggest headline is Takeda's leap into AI-driven drug discovery. The Japanese pharmaceutical giant has signed a partnership with Insilico Medicine, the Hong Kong-based biotech, in a deal that could be worth up to $600 million. Takeda will tap Insilico's artificial intelligence platform to identify and speed the search for promising new medicines — a marquee validation of the idea that AI can compress the earliest, slowest stages of drug hunting.
Takeda isn't alone. India's Mankind Pharma, one of the country's largest drugmakers, has teamed with Armenian startup Denovo Sciences to launch its own AI-led discovery programme. Taken together, the two deals show the trend spreading well beyond Silicon Valley and traditional Western pharma hubs.
But the enthusiasm comes with a question mark. Two fresh commentaries capture the mood: AI is moving from buzzword to genuine working tool inside pharma, yet it remains unclear whether the boom will ultimately pay off in approved drugs and returns. And the technology's reach is widening — one survey of the field notes AI now spans the full arc of medicine, from discovery all the way to the bedside and the delivery of care itself.
Clinical Readouts Deliver
While AI grabs the spotlight, old-fashioned trial data did the heavy lifting elsewhere. Roche reported that its experimental drug divarasib succeeded in a Phase 3 head-to-head study in non-small cell lung cancer — the most common form of the disease — beating its rivals and strengthening Roche's hand in a fiercely competitive space.
Revolution Medicines offered its first public look at the early data that convinced it to push a combination of two KRAS-targeting drugs into late-stage testing, a closely watched bet in one of oncology's hottest areas. And Otsuka unveiled new long-term results for its kidney disease drug Voyxact, hoping the durability of the data can convert the treatment's accelerated approval into a full one.
Money and Markets Move
The financing and business side was equally busy. Celea Therapeutics, a PureTech spinout, raised $180 million to develop a new treatment for idiopathic pulmonary fibrosis, the progressive lung-scarring disease that has frustrated drugmakers for years.
Investors will also be watching Scribe Therapeutics, a developer of novel CRISPR gene-editing enzymes, which filed late Thursday for an IPO on the Nasdaq — an early test of Wall Street's appetite for young, unproven biotech.
Finally, generics maker Sandoz is going straight to patients, launching a direct-to-consumer platform that starts with a single medication for a growth disorder. It's a modest first step, but it puts Sandoz alongside a growing roster of drugmakers trying to sell directly to the people who take their pills.
The throughline today: AI is reshaping how drugs get discovered, but the clinic still decides which ones win.